What is StrideBio?
StrideBio operates at the vanguard of gene therapy development, leveraging its proprietary STRIVE Capsid Platform to engineer next-generation adeno-associated virus (AAV) vectors. By focusing on superior drug development and high-fidelity manufacturing, the company aims to overcome traditional limitations in gene delivery, thereby enhancing the efficacy and safety profiles of treatments for rare and severe diseases. StrideBio's market position is defined by its commitment to scientific integrity and its ability to translate complex biological research into scalable, clinical-grade therapeutic solutions that address significant unmet medical needs.
How much funding has StrideBio raised?
StrideBio has raised a total of $97.2M across 2 funding rounds:
Series A
$15.7M
Series B
$81.5M
Series A (2018): $15.7M with participation from UCB, Takeda Ventures, Alexandria Venture Investments, and Hatteras Venture Partners
Series B (2021): $81.5M led by UF Innovate Ventures, Caas Capital Management, Novo Holdings, Northpond Ventures, Octagon Capital, Sarepta Therapeutics, and Pontifax
Key Investors in StrideBio
Sarepta Therapeutics
A global commercial-stage biopharmaceutical company specializing in precision genetic medicines for rare diseases, with a deep focus on neuromuscular and central nervous system disorders.
Pontifax
A venture capital firm dedicated to life sciences, providing strategic guidance and capital to clinical-stage companies developing disruptive healthcare technologies.
Takeda Ventures
The corporate venture arm of a global pharmaceutical leader, focusing on research and development in gastroenterology, oncology, neuroscience, and rare disease therapies.
What's next for StrideBio?
The recent capital injection serves as a catalyst for StrideBio to transition its lead candidates through critical clinical milestones while expanding its AAV manufacturing infrastructure. By aligning with high-caliber biopharmaceutical partners and specialized life science investors, the company is well-positioned to scale its operations and refine its platform technology. Future strategic initiatives will likely prioritize the diversification of its therapeutic portfolio and the strengthening of its intellectual property moat, ensuring that StrideBio remains a leader in the rapidly evolving field of precision genetic medicine.
See full StrideBio company page
